Panacea Biotec Limited (NSE:PANACEABIO)
India · Delayed Price · Currency is INR 358.50
-7.50 (-2.05%)
Oct 1, 2026, 3:29 PM IST
Panacea Biotec Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 6,726 | 6,398 | 5,591 | 5,592 | 4,599 | 6,612 |
Revenue Growth | 10.26% | 14.43% | -0.01% | 21.57% | -30.44% | 5.83% |
Gross Profit Gross Profit Growth | 3,677 | 3,593 | 3,596 | 3,290 | 2,073 | 3,990 |
Operating Income Operating Income Growth | -303.8 | -269.86 | -529.78 | -414.69 | -1,027 | -484.18 |
Net Income Net Income Growth | -71.2 | -53.77 | -83.7 | -11.73 | -332.37 | 10,783 |
Earnings Per Share EPS Growth | -1.17 | -0.88 | -1.37 | -0.19 | -5.43 | 176.05 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Vaccines Vaccines Growth | 4,327 | 4,103 | 3,098 | 3,596 | 2,570 | 2,348 |
Pharmaceutical Formulations & Nutrition Pharmaceutical Formulations & Nutrition Growth | 2,400 | 2,295 | 2,493 | 1,996 | 2,030 | 4,265 |
Total Total Growth | 6,726 | 6,398 | 5,591 | 5,592 | 4,599 | 6,612 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 744 | 682.57 | 1,294 | 1,514 | 2,130 | 5,516 |
Total Debt Total Debt Growth | 236.6 | 236.64 | 222.06 | 209.94 | 202.19 | 341.55 |
Net Cash (Debt) Net Cash Growth | 507.4 | 445.93 | 1,072 | 1,304 | 1,928 | 5,175 |
Net Cash Growth | -42.28% | -58.39% | -17.85% | -32.35% | -62.74% | - |
Net Cash Per Share Net Cash Per Share Growth | 8.34 | 7.28 | 17.50 | 21.30 | 31.48 | 84.48 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | - | 166.94 | -273.69 | 34.68 | -4,225 | -1,084 |
Capital Expenditures CapEx Growth | - | -540.89 | -503.05 | -828.76 | -409.46 | -125.1 |
Free Cash Flow Free Cash Flow Growth | - | -373.95 | -776.74 | -794.08 | -4,634 | -1,210 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 54.66% | 56.16% | 64.31% | 58.85% | 45.07% | 60.35% |
Operating Margin | -4.52% | -4.22% | -9.48% | -7.42% | -22.34% | -7.32% |
Pretax Margin | -1.54% | -1.15% | -1.42% | 0.26% | 2.78% | 219.19% |
Profit Margin | -1.06% | -0.84% | -1.50% | -0.21% | -7.23% | 163.08% |
FCF Margin | - | -5.85% | -13.89% | -14.20% | -100.75% | -18.29% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | - | - | - | 0.84 |
PS Ratio | 3.27 | 2.83 | 4.83 | 1.33 | 1.44 | 1.37 |